Skip to main content


Close up of mixed medications

09-12-2022 | Medications | News

TriMaster data support ‘try before you choose’ for type 2 diabetes medications

Allowing people to try out medications for type 2 diabetes and choose their preferred one is a viable approach in the absence of a clear clinical indication, say the TriMaster investigators.

Senior woman using video conference (telehealth concept)

28-02-2022 | Canagliflozin | News

Virtual CHIEF-HF trial supports canagliflozin in heart failure

The virtual CHIEF-HF trial has demonstrated a significant positive effect of canagliflozin on heart failure symptoms without the need for in-person clinic visits, the investigators report in Nature Medicine.

Arrow on target

29-09-2021 | EASD 2021 | Conference coverage | News

TriMaster supports precision medicine strategy for type 2 diabetes treatment intensification

Findings from the TriMaster trial suggest that stratification of people with type 2 diabetes based on clinical features may help to guide the choice of second- or third-line drug for those who require treatment intensification after metformin.

26-08-2021 | ESC 2021 | Conference coverage | News

Canagliflozin may protect against hyperkalemia in type 2 diabetes with CKD

Canagliflozin may reduce the risk for hyperkalemia, without increasing hypokalemia, in people with type 2 diabetes and chronic kidney disease receiving renin–angiotensin–aldosterone system inhibitors, shows a CREDENCE post-hoc analysis.

Sphygmomanometer on blue, reflective table with black background

22-02-2021 | Canagliflozin | News

Antihypertensive effect for canagliflozin in diabetic renal disease

The SGLT2 inhibitor canagliflozin reduces blood pressure and the need for additional antihypertensives in people with type 2 diabetes and chronic kidney disease, research suggests.

17-12-2020 | Canagliflozin | News

Model demonstrates cost-effectiveness of canagliflozin in type 2 diabetes

Adding canagliflozin to current standard of care improves survival, increases quality-adjusted life–years, and reduces treatment costs for people with type 2 diabetes treated in England over a 10-year period, research suggests.

23-11-2020 | Canagliflozin | News

SGLT2 inhibition may slow decline of advanced diabetic kidney disease

A post-hoc analysis of the CREDENCE trial suggests that canagliflozin could be beneficial in people with advanced diabetic kidney disease.

28-10-2020 | Canagliflozin | News

Canagliflozin linked to reduced anemia risk in people with type 2 diabetes, CKD

Treatment with the SGLT2 inhibitor canagliflozin is associated with a reduced risk for anemia-related outcomes among people with type 2 diabetes and chronic kidney disease, suggests a post-hoc analysis of the CREDENCE trial.